Rokos Capital Management LLP Purchases New Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Rokos Capital Management LLP acquired a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,335 shares of the company’s stock, valued at approximately $4,256,000.

Other hedge funds also recently added to or reduced their stakes in the company. Cetera Investment Advisers purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at approximately $455,000. Rhumbline Advisers purchased a new stake in shares of BeOne Medicines during the second quarter worth approximately $275,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of BeOne Medicines during the second quarter worth $505,000. Invesco Ltd. acquired a new stake in shares of BeOne Medicines during the second quarter worth $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines in the 2nd quarter valued at $68,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BeOne Medicines

In other news, COO Xiaobin Wu sold 1,484 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $269.37, for a total transaction of $399,745.08. Following the sale, the chief operating officer owned 40 shares of the company’s stock, valued at $10,774.80. The trade was a 97.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the sale, the chief executive officer directly owned 8,122 shares in the company, valued at $2,484,925.90. This trade represents a 94.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 233,647 shares of company stock valued at $70,335,553. Corporate insiders own 6.19% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ONC shares. Barclays dropped their price objective on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 14th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $396.00 target price on shares of BeOne Medicines in a report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Finally, Royal Bank Of Canada boosted their price target on shares of BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and a consensus target price of $394.00.

BeOne Medicines Stock Performance

Shares of ONC opened at $325.90 on Tuesday. The company has a 50-day simple moving average of $292.10 and a 200-day simple moving average of $309.39. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $35.76 billion, a PE ratio of 72.91 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.